# AI Discovery for Next-Generation Cancer Treatments

> We use our proprietary platform to discover unexplored, clinically relevant, cancer-specific epitopes in different types of drug resistant tumors and to generate antibodies with atomic-level specificity to these epitopes.

## Pages

- [Home](https://www.sanavia.bio/): We use our proprietary platform to discover unexplored, clinically relevant, cancer-specific epitopes in different types of drug resistant tumors and to generate antibodies with atomic-level specificity to these epitopes.
- [TEST](https://www.sanavia.bio/test)
- [What We Do ](https://www.sanavia.bio/what-we-do): At Sanavia we use our proprietary platform to discover unexplored, clinically relevant, cancer-specific epitopes in different types of drug resistant tumors and to generate antibodies with atomic-level specificity to these epitopes.
- [About](https://www.sanavia.bio/about): Behind every trial and every breakthrough, there’s a wife, a brother, a mother—someone who’s run out of options but not out of hope. So we push harder for the cures that are still out of reach. Because every patient deserves more than time. They deserve a chance.
- [Contact](https://www.sanavia.bio/contact): We believe in the power of connections and the transformation they can bring. We look forward to connecting with you and working together to revolutionize the future of oncology.
- [SANA-01 ADC](https://www.sanavia.bio/sana-01): Our Epitope Discovery Platform revealed a more stable, first-in-class MUC-1 epitope in cancers. And it’s already redefining what’s possible for therapeutic antibody development for solid tumors.
- [Privacy Policy](https://www.sanavia.bio/privacy-policy): Learn more about our privacy policy